This is a follow-up study of subjects who received NTLA-2002 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. A subject has completed or discontinued from an Intellia-sponsored or -supported treatment protocol in which a complete or partial dose of NTLA-2002 was received.
2. A subject has provided informed consent for the LTFU study.
3. A subject is willing to attend study visits, complete protocol-required follow-up schedule, and comply with the study requirements.
Exclusion Criteria:
None
Primary outcome measure(s)
Incidence of treatment-related Adverse Events (AEs); incidence of treatment-related Serious Adverse Events (SAEs); incidence of treatment-related Adverse Events of Special Interest (AESIs) defined per protocol — up to 15 years
Trial sites (7)
Facility
City
Region
Status
Campbelltown Hospital
Campbelltown
New South Wales
Centre National de Reference - Grenoble
Grenoble
France
Hôpital Claude Huriez
Lille
France
Charite-Universitätsmedizin Berlin
Berlin
Germany
University of Amsterdam Academic Medical Center
Amsterdam
Netherlands
New Zealand Clinical Research
Auckland
New Zealand
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.